Sage Therapeutics Plunges 12.3% on Disappointing Study Results
Generated by AI AgentAinvest Movers Radar
Tuesday, Mar 25, 2025 6:43 am ET1min read
SAGE--
On March 25, 2025, Sage TherapeuticsSAGE-- experienced a significant drop of 12.3% in pre-market trading.
Sage Therapeutics recently announced disappointing results from the Phase 2 KINETIC 2 Study of its investigational drug SAGE-324 for the chronic treatment of essential tremor (ET). This news has raised concerns among investors about the company's pipeline and future prospects.
Additionally, Sage Therapeutics has entered into a licensing agreement with BiogenBIIB-- to jointly develop and commercialize zuranolone (SAGE-217). This collaboration is aimed at leveraging the strengths of both companies to bring innovative treatments to patients.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet